Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27922371 | 0.91 | CYP19A1 (0.38) | CYP19A1ALDH1A1CACNA1BMEN1CYP1A2 | |
| SCHEMBL14991463 | 0.89 | TPSAB1 (0.41) | CYP19A1ALDH1A1CACNA1BMEN1CYP1A2 | |
| SCHEMBL1199017 | 0.80 | CACNA1B (0.47) | CYP19A1CACNA1BMEN1KMT2APRSS1 | |
| SCHEMBL1200268 | 0.79 | NPY1R (0.41) | CYP19A1CACNA1BCHRM3NPC1HTT | |
| SCHEMBL13667863 | 0.77 | CYP19A1 (0.38) | CYP19A1ALDH1A1CACNA1BCHRM3NPC1 | |
| SCHEMBL1199727 | 0.77 | TAAR1 (0.44) | CYP19A1MEN1KMT2ACHRM3NPC1 | |
| SCHEMBL15004577 | 0.76 | HSP90AA1 (0.40) | MAPT | |
| SCHEMBL14856252 | 0.76 | HSP90AA1 (0.56) | CYP1A2CYP3A4MAPT | |
| SCHEMBL1133987 | 0.74 | LMNA (0.39) | MEN1CYP1A2KMT2ACHRM3LMNA | |
| SCHEMBL1198777 | 0.74 | CHEK1 (0.57) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580193-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| EP-2580193-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-07-07 | — | — | US | disclosed |
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-07-07 | — | — | US | disclosed |
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | disclosed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | disclosed |
| EP-2580193-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | Chroma Therapeutics Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154708-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154708-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | CYP19A1 387/4885ALDH1A1 1146/4885CACNA1B 4510/4885 |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | CYP19A1 387/4885ALDH1A1 1146/4885CACNA1B 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.